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TARGETING THE MAJOR REGULATOR OF MITOSIS 
J. Mason Hoffman 
July 27, 2017 
Mitosis-inhibiting chemotherapeutics (e.g. taxanes) are frequently used to 
treat multiple cancer types. Recently, there has been much concern about the 
limited success of these drugs due to resistance and a lack of molecular targets. 
Thus, there is high demand for new drugs with diverse cellular targets. Targeting 
the regulators of mitosis is a promising approach. The anaphase promoting 
complex/cyclosome (APC/C) is an E3 ubiquitin ligase that controls cell cycle 
progression at multiple points. The interaction of ANAPC2 and ANAPC11, 
catalytic core subunits, is necessary for APC/C function. An in silico approach 
was used to identify compounds predicted to prevent assembly of ANAPC2 and 
ANAPC11, causing APC/C inhibition and mitotic arrest. Several of the predicted 
compounds possess cytotoxic properties in multiple cancer cell types. These hit 
compounds induce mitotic arrest and cell death in malignant, but not non-
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Mitosis-inhibiting chemotherapeutics (e.g. taxanes) are frequently used in 
combination chemotherapy to treat multiple types of cancer. These are effective 
because they exploit the mitotic spindle assembly checkpoint (SAC), causing 
inhibition of the anaphase promoting complex/cyclosome (APC/C), mitotic arrest, 
and apoptosis. Successful therapy is often hindered by drug-resistant tumors, 
neurotoxicity, and limited supply. All current mitotic inhibitors, and the majority 
that are in development, target a single protein: tubulin. Therefore, mutations in 
tubulin or SAC proteins create cancer cells that are resistant to all current mitotic 
inhibitors. Thus, there is high demand for new drugs with diverse cellular targets. 
Rather than targeting tubulin, a promising alternative approach is targeting the 
proteins that regulate mitosis. The APC/C is an E3 ubiquitin ligase that is vital for 
progression through mitosis and G1-phase. The APC/C ubiquitinylates its protein 
targets, which marks them for degradation. Many target proteins of the APC/C 
have well characterized proliferative or anti-proliferative roles. By carefully 
orchestrating the degradation of these proteins, the APC/C facilitates the orderly 
progression of the cell cycle and timing of critical cellular events. 
The Ubiquitin-Proteasome System and the Cell Cycle 
The cell cycle is a highly regulated unidirectional sequence of events in 
which a cell replicates its genetic material and divides into two daughter cells. A 
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complex network of proteins is required to coordinate progression through each 
phase of this process. In eukaryotic cells, the cell cycle is divided into four 
phases: G1 (gap 1), S (Synthesis, DNA replication), G2 (gap 2), and M (Mitosis, 
division of cellular components to two daughter cells).  
Of particular importance in controlling phase transitions are a family of 
protein kinases, known as cyclin-dependent kinases (CDKs). CDKs are 
constitutively-expressed and regulate the activity of their targets by 
phosphorylation. As their name suggests, they are only active when associated 
with positive regulatory subunits, known as cyclins [1]. The prototypical cyclins 
involved in cell cycle control are cyclins A, B, D, and E, each of which associates 
with different CDKs. Expression of cyclins, unlike CDKs, oscillates during each 
cell cycle resulting in activation of different CDKs at unique times. Thus, through 
their control of CDK activity, cyclins are key to promoting cell cycle progression. 
This pattern of CDK activation allows phosphorylation of key targets involved in 
DNA replication and mitosis at the appropriate times. Further complicating 
matters, CDK activity is negatively regulated by post-translational modifications 
(PTMs, e.g. phosphorylation) and the periodic expression of CDK inhibitors 
(CDKNs) [2]. A delicate balance between synthesis and degradation of cyclins, 
CDKNs, and other regulatory proteins is required for cell cycle control [1, 3].  
Perhaps the most important means of CDK regulation is the periodic 
degradation of cyclins and CDKNs by ubiquitin-mediated proteolysis [4, 5]. 
Ubiquitin is a small, highly-conserved protein that is covalently attached to a 
target protein through a process called ubiquitinylation. It is the slowest evolving 
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protein yet identified, highlighting the conserved importance of its function. 
Ubiquitinylation, like other PTMs, can alter the stability, structure, localization and 
function of target proteins [6, 7]. More specifically, ubiquitinylation is the 
formation of an isopeptide bond between the C-terminus of ubiquitin and a lysine 
within a confined domain of the target. Polyubiquitinylation is a modification 
which contains chains of multiple linked ubiquitins [6, 8, 9]. In terms of cell cycle 
control, the predominant function of polyubiquitinylation is to mark target proteins, 
such as cyclins, CDKNs, and other key regulatory proteins, for degradation [10].  
While polyubiquitination can have numerous cellular effects, one of the 
most studied roles of polyubiquitination is in protein degradation. Other functions 
of ubiquitinylation include enzyme activation, epigenetic modification, receptor 
internalization, apoptosis, polycomb silencing, and signaling pathways such as 
tumor necrosis factor, interleukin 1 beta, CD40 ligand, Toll-like receptors, and 
Nucleotide-binding oligomerization domain-containing protein 2 [11-15]. As would 
be expected of a system that regulates so many important cellular processes, 
there is a large and growing list of proteins involved in this process of 
ubiquitinylation and degradation of target proteins. These proteins comprise what 
is known as the ubiquitin-proteasome system (UPS). This system of selective, 
programmed protein degradation ensures the unidirectionality of the cell cycle 
and the appropriate timing of cell cycle events [5, 10, 16]. 
The ubiquitin-proteasome system facilitates the degradation of target 
proteins by directing them to the 26S proteasome, a large multi-subunit complex 
consisting of multiple proteases [17, 18]. The core of the proteasome, termed the 
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20S proteasome, contains chymotrypsin-like, trypsin-like, and caspase-like 
enzymatic activities [17]. The 26S proteasome is formed by association of two 
19S caps with opposite ends of the 20S core [7]. These caps act as regulatory 
subunits for recognition of ubiquitinylated proteins. Upon recognition, the protein 
is unfolded in an ATP-dependent manner by the 19S subunits and introduced 
into the inner chamber of the 20S subunit for degradation. While rare cases of 
ubiquitin-independent proteasomal degradation have been documented, most 
cases rely on signaling via protein ubiquitinylation [17]. 
Ubiquitinylation of a target protein is facilitated by a 3-step cascade of 
enzymatic reactions (Figure 1) [7]. The initial step requires a ubiquitin-activating 
enzyme (E1), which binds to the C-terminal glycine of ubiquitin via an ATP-
dependent reaction [19]. Following activation, ubiquitin is transferred from the E1 
to a ubiquitin-conjugating enzyme (E2), and finally, an E3 ubiquitin ligase 
transfers ubiquitin from the E2 to the target protein [20]. Multiple rounds of 
ubiquitinylation occur, allowing the target protein to be recognized and degraded 
by the 26S proteasome (Figure 1). E3 ubiquitin ligases provide the UPS with a 
high degree of specificity, which is required for this system to target the correct 
proteins at the appropriate times [6, 7]. 
E3 ubiquitin ligases, enzymes responsible for the transfer of ubiquitin from 
an E2 ubiquitin-conjugating enzyme to the target protein, are the largest and  
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Figure 1. Outline of protein degradation by the ubiquitin proteasome 
system. E1 ubiquitin-activating enzymes first covalently attach to ubiquitin via an 
ATP-dependent reaction. Ubiquitin is then transferred to an E2 ubiquitin-
conjugating enzyme. An E3 ubiquitin ligase binds its substrate protein and the 
ubiquitin-bound E2 enzyme and catalyzes the covalent attachment of ubiquitin to 
the substrate. Multiple rounds of substrate ubiquitinylation lead to the formation 
of a polyubiquitin chain. The polyubiquitinylated substrate is subsequently 
recognized and degraded by the 26S proteasome. The E3 ubiquitin ligase is now 
free to repeat the cycle from the beginning. The four main classes of E3 ubiquitin 
ligases (HECT, PHD-finger, RING-finger, and U-box types) and the members of 
the RING-finger E3 subfamily (APC/C, SCF, ECV, CUL3-based, CUL4-based, 
ECS, CUL7-based, and PARC E3s) are listed. The two RING-finger E3s in bold, 
the APC/C and SCF, are both critical for cell cycle regulation.   
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most complex members of the E1-E2-E3 cascade [21]. While humans possess 
only 8 E1 ubiquitin-activating enzymes and 38 E2 ubiquitin-conjugating enzymes, 
there are more than 600 human E3 ubiquitin ligases [19, 20]. There are four 
classes of E3 ubiquitin ligases: HECT (homologous to E6-AP C-terminus) 
domain-containingE3s, U-box domain-containing E3s, PHD (plant homeodomain) 
finger domain-containing E3s, and RING (really interesting new gene) finger-
containing E3s (Figure 1) [21].  
The RING finger E3s are the largest E3 class and are further divided into 
subclasses (Figure 1). One of these is the cullin-RING ligase (CRL) subclass, 
which includes two structurally similar protein complexes that are vital to cell 
cycle regulation: The SKP/cullin/F-box-containing (SCF) complexes and the 
anaphase promoting complex/cyclosome (APC/C) (Figure 1) [21]. The catalytic 
cores of these CRLs are highly similar, consisting of a cullin-like protein and a 
Zn-RING-finger protein [21, 22]. Cullin and Zn-RING-finger proteins are essential 
for catalyzing the transfer of ubiquitin to the target protein [23]. Additionally, these 
E3 ubiquitin ligases associate with specific coactivator subunits, which determine 
substrate specificity [24-26].  
E3 ubiquitin ligases, like CDKs, are subject to multiple layers of regulation, 
including activating and inhibitory PTMs, association with coactivators and 
inhibitors, and periodic expression of various subunits [24-30]. Additionally, 
deubiquitinating enzymes (DUBs), proteases that cleave ubiquitin from modified 
proteins, directly counteract E3 ubiquitin ligases. In humans, over 100 DUBs 
have been identified, each targeting specific subsets of proteins. DUBs have 
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demonstrated roles in many cellular processes, including DNA repair, chromatin 
remodeling, various signaling pathways, and cell cycle regulation [31]. A study by 
Huang et. al provided an example of the importance of DUBs in cell cycle 
regulation [32]. Briefly, they showed that ubiquitin carboxyl-terminal hydrolase 37 
(USP37), a DUB that both antagonizes and is a substrate of the APC/C, is 
important for regulation of S-phase entry [32]. USP37 is fully activated at G1/S by 
phosphorylation by CDK2/cyclin E or CDK2/cyclin A, allowing it to stabilize cyclin 
A by deubiquitylation, promoting entry into S-phase. In mitosis, CDK2 inactivation 
leads to loss of USP37 activity and its degradation as an APC/C substrate. This 
prevents USP37 from antagonizing the APC/C, allowing timely degradation of 
key APC/C mitotic substrates, and promoting mitotic progression. Several other 
examples of DUBs in cell cycle regulation are detailed by Wei et. al [31]. 
The remainder of this section will focus on the role of CRLs in cell cycle 
regulation, control of CRL activity, and particularly, the APC/C in regulation of 
mitosis. 
Two Cullin-RING Ligases Control Cell Cycle Progression  
SCF E3 Ubiquitin Ligases are critical components of cell cycle regulation. 
They are particularly important for regulating entry into S-phase, as well as 
mitotic entry [29, 33]. There are three core components of SCF ligases which are 
invariable: SKP1 (S-phase kinase-associated protein 1), CUL1 (Cullin-1), and 
RBX1 (RING-box protein 1) [34]. SCF ligases are the largest class of E3 ligases 
and are responsible for the degradation of an estimated 20% of ubiquitin-
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proteasome-regulated proteins, including many cell cycle regulatory proteins 
(Table 1) [6, 7, 35-37].  
SCF complexes are classified as CUL1-containing E3 ubiquitin ligases. 
CUL1 is a cullin protein that functions as a scaffold protein. In addition to CUL1, 
SCF ubiquitin ligases contain RBX1, a RING-finger protein, and SKP1, an 
adaptor protein that binds F-box proteins [37]. There are at least 69 human F-box 
proteins, each with a conserved C-terminal F-box motif for binding SKP1. F-box 
proteins function as the SCF substrate determining subunit and are divided into 
three subfamilies based on their C-terminal substrate binding domains: the 
FBXW (WD40 substrate binding domains), FBXL (leucine-rich repeats (LRR) 
substrate binding domains), and FBXO (contains other binding domains such as 
kelch repeats or proline-rich repeats) subfamilies [37-39]. Each F-box protein 
recognizes a different set of substrates depending on which substrate binding 
domains they contain. Interestingly, there is an overlap in substrate recognition, 
allowing one substrate to be targeted by multiple F-box proteins. Because all 
three subfamilies of F-box proteins are implicated in cell cycle control, these SCF 
complexes are likely to be ineffective as a chemotherapeutic target due to the 
redundancy of F-box substrate-targeting. 
  SCF E3s containing FBXW1 (SCF(FBXW1)), also known as β-
TrCP (beta-transducin repeat containing protein), have been well documented for 
their role in cell cycle control. FBXW1 is highly homologous to APC/C substrate 
specificity subunits, CDC20 (cell division cycle 20) and CDH1 (CDC20 homolog 
1) [40], which will be discussed in the following paragraphs. SCF(FBXW1) 
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complexes have been implicated in the targeting of numerous cell cycle 
regulators including EMI1/FBXO5 (early mitotic inhibitor 1/ F-box only protein 5), 
WEE1 (Wee1-like protein kinase), CDC25A (cell division cycle 25A), Cyclin D1, 
PLK4 (polo-like kinase 4), BORA (protein aurora borealis), and Securin (Table 1) 
[37]. EMI1 is an inhibitor of the APC/C in S and G2 phase. In prophase, 
degradation of EMI1 mediated by SCF(FBXW1) is required for activation of the 
APC/C and mitotic progression [41]. This is one of many examples of the 
complex co-regulatory network between SCF complexes and the APC/C [4, 26, 
42]. Similarly, FBXW1-dependent degradation of WEE1 kinase, a negative 
regulator of mitotic entry, is required for cells to transition from G2 to M [43]. 
Another SCF(FBXW1) target, PLK4, is a serine/threonine protein kinase critical 
for centriole duplication [44]. SCF(FBXW1) has been found to target PLK4 for 
degradation, which prevents centriole amplification and chromosomal instability 
[45, 46]. Securin is an inhibitor of the metaphase to anaphase transition in 
mitosis, and is well-documented as a mitotic substrate of the APC/C [40, 47-53]. 
However, in response to UV irradiation, securin degradation was found to be 
mediated by SCF(FBXW1), resulting in cell cycle arrest [54, 55]. CDC25A 
degradation is required for entry into S-phase. In response to DNA damage, 
CDC25A is phosphorylated, allowing its recognition by SCF(FBXW1), leading to 
delayed S-phase entry [56, 57]. Another member of the FBXW F-box protein 
subfamily, FBXW7, targets several key cell cycle regulators. Cyclin E, an 
activator of CDK2, promotes the G1/S-phase transition and its phosphorylated 





Table 1 Reported substrates of each F-box subfamily. 
































Aurora kinases A and B are important regulators of mitosis that ensure proper 
segregation of chromosomes, and both have been identified as SCF(FBXW7) 
targets [59-62].  
FBXL proteins, a 22-member F-box subfamily, are equally important as 
the FBXW subfamily. Targets of these FBXL proteins include multiple CDKNs, 
cyclins, and various cell cycle kinases (Table 1) [21, 37]. The most studied 
member of this subfamily is FBXL1, also called Skp2. Degradation of CDKN1B 
(Cyclin-dependent Kinase Inhibitor 1B, p27Kip1) is reportedly mediated by FBXL1, 
a step required for S-phase entry, [63, 64]. Other negative regulators of the cell 
cycle, such as the CDK inhibitors CDKN1A (Cyclin-dependent Kinase Inhibitor 
1A, p21CIP1) and CDKN1C (Cyclin-dependent Kinase Inhibitor 1C, p57Kip2), have 
been documented as FBXL1 targets [65, 66]. Degradation of these proteins 
promotes cell cycle progression in S and G2 phases. Numerous other targets of 
FBXL-containing SCF complexes have been reported and are reviewed by 
Nakayama et.al [67] and Zheng et. al [37]. Like the SCF(FBXW) complexes, the 
SCF(FBXL) complexes are intertwined in a complex regulatory network with the 
APC/C. For example, degradation of FBXL1 is mediated by the APC/C in G1-
phase [29]. Therefore, SCF(FBXL1) becomes inactivated and is only reactivated 
when APC/C activity decreases and FBXL1 is stabilized. 
The third subfamily of F-box proteins is FBXO, or F-box only. Unlike 
FBXW proteins, which contain only C-terminal WD40 (structural motif terminating 
in W-D dipeptide) motifs, and FBXL proteins, which contain only C-terminal LRR 
(leucine-rich repeat) motifs, FBXO proteins can possess any of 21 other 
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homology domains for substrate recognition. There are at least 36 FBXO 
proteins, many of which are not well understood. However, what is known about 
FBXO proteins demonstrates their importance in cell cycle regulation (Table 1) 
[37]. FBXO1, or Cyclin F, contains an amino acid sequence similar to that of 
Cyclin A and its protein levels oscillate throughout the cell cycle, increasing in S, 
peaking in G2, and disappearing in mitosis [68, 69]. FBXO1 has been reported to 
bind Cyclin B and facilitate its nuclear import, implicating it in regulation of mitotic 
entry [70]. The relationship between SCF complexes and the APC/C is further 
complicated by the fact that FBXO5 (also called EMI1, see above) is an APC/C 
inhibitor and is itself targeted for degradation by a separate SCF complex 
containing FBXW1 [37, 41]. FBXO5, through regulation of APC/C activity, helps 
to control mitosis by regulating levels of Cyclin A, Cyclin B, securin, and other 
mitotic targets of the APC/C. Other notable targets of FBXO proteins include 
TP53, MDM2 (mouse double minute 2), BRCA1 (breast cancer type 1 
susceptibility protein), Cyclin D, CHK1 (checkpoint kinase-1), and CDT1 
(chromatin licensing and DNA replication factor 1) [37].  
The APC/C controls the cell cycle in mitosis and G1-phase and is the 
counterpart to SCF complexes, which are largely responsible for regulation of S- 
and G2-phase progression. The APC/C is a large multi-subunit E3 ubiquitin 
ligase that is essential for proliferation and is the master regulator of mitosis [4, 
24, 48, 52, 53]. It also plays a role in promoting the G1 progression [2, 27, 71-
74]. An atomic structure of the full complex was determined in 2015, providing 
insights into the structural and functional roles of each subunit [75]. The APC/C 
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has at least 14 subunits that assemble into a 1.5 MDa complex [40]. Within the 
complex, individual subunits may be grouped into 3 sub-complexes: scaffolding, 
catalytic and substrate recognition, and tetratricopeptide repeat (TPR) arm sub-
complexes [40, 53]. The catalytic sub-complex contains ANAPC10 and, like SCF 
complexes, has a cullin-like subunit, ANAPC2, and a RING-finger subunit, 
ANAPC11. The scaffolding sub-complex is made up of ANAPC1, ANAPC4, and 
ANAPC5. The TPR arm, which provides binding sites for scaffolding subunits 
and coactivators, consists of ANAPC3, ANAPC6, and ANAPC8. In contrast to the 
approximately 70 F-box proteins that determine substrates for SCF complexes, 
APC/C substrate selection is determined primarily by association with one of two 
coactivators: CDC20 and CDH1 [25, 76, 77]. 
In mitosis, numerous steps are required for full APC/C activation including 
degradation of inhibitors, association with coactivators, and phosphorylation of 
core subunits [4]. In G2 and early mitosis, the APC/C binds CDC20 
(APC/C(CDC20)), which functions as its substrate selectivity subunit (Table 2) 
[24, 78]. CDC20 contains a WD40 repeat domain, which is responsible for 
binding substrate D-box destruction motifs (RXXLXXXXN) [24]. As previously 
mentioned, APC/C(CDC20) is inhibited by EMI1 (FBXO5), which prevents 
substrate recognition by CDC20 and allows mitotic cyclins to accumulate, driving 
CDK1 activity and mitotic progression [37, 41, 79]. EMI1 is subsequently 
phosphorylated in early mitosis by CDK1-Cyclin B and polo-like kinases (PLKs) 
targeting it for SCF(FBXW1)-mediated ubiquitinylation [80, 81]. Degradation of 




Table 2. List of reported APC/C(CDC20) and APC/C(CDH1) targets 























APC/C(CDC20) fully, the mitotic checkpoint, or spindle-assembly checkpoint 
must be satisfied [28, 82, 83]. The SAC functions to prevent unequal segregation 
of genetic material between two daughter cells by inhibiting APC/C(CDC20) until 
the cell has achieved proper attachment of mitotic spindle microtubules to all 
sister chromatids [84, 85]. Briefly, the SAC possesses a sensory mechanism that 
detects unattached kinetochores, promoting formation of a multisubunit mitotic 
checkpoint complex (MCC) that halts mitotic progression by inhibiting 
APC/C(CDC20). The interplay between the SAC and the APC/C is complex will 
be described in the following paragraphs. Once the SAC is satisfied, the MCC 
disassembles and the APC/C is phosphorylated at no fewer than 34 mitosis-
specific sites [86]. Kraft et. al found that of these 34 sites, 15 can be 
phosphorylated by CDK1 and 3 by Plk1, but full activation requires 
phosphorylation only at CDK1 sites [86]. Fully activated APC/C(CDC20), in a 
negative feedback loop, targets Cyclin B for degradation, leading to CDK1 
inactivation and promoting mitotic exit [47, 48, 50, 51]. Concurrently, 
APC/C(CDC20) also targets securin, an inhibitor of the cysteine protease 
separase [49]. APC/C(CDC20)-mediated degradation of securin activates 
separase, which then cleaves cohesion subunit RAD21 (double-strand-break 
repair protein rad21 homolog), allowing separation of sister chromatids and 
promoting anaphase progression [87].  
Prior to APC/C activation, CDH1, the second APC/C coactivator, is 
maintained in a phosphorylated form by CDK1, preventing its association with the 
APC/C. Following APC/C(CDC20)-mediated Cyclin B degradation and CDK1 
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inactivation, CDH1 is dephosphorylated, allowing its association with the APC/C 
(APC/C(CDH1)) [27, 88, 89]. CDC20 is a substrate of APC/C(CDH1), and its 
degradation allows CDH1 to take over as the substrate specificity subunit (Table 
2) [27, 74, 78]. Additionally, as previously mentioned, APC/C(CDC20) relies on 
phosphorylation to become active, whereas phosphorylation inhibits binding of 
CDH1. The opposite regulation of CDC20 and CDH1 by phosphorylation is a 
major factor that allows for the quick exchange of the two coactivators. CDH1, 
like CDC20, contains WD40 repeats that recognize substrate D-box destruction 
motifs, but it can also recognize KEN-box motifs (KENXXXN) [25]. In late mitosis, 
APC/C(CDH1) continues to target Cyclin B degradation, keeping CDK1 activity 
low [90]. Many critical regulators of cytokinesis, centrosome replication, and 
mitotic spindle movement have been documented as APC/C(CDH1) targets [52]. 
In anaphase, PLK1 is targeted for destruction by APC/C(CDH1), allowing 
dephosphorylation of proteins involved in elongation of the mitotic spindle [91]. 
During mitotic exit, APC/C(CDH1) substrates include both Aurora A and Aurora B 
mitotic kinases, Kinesin-like protein KIFC1 (kinesin family member C1), and the 
actin-binding protein anillin [92-96]. By promoting the degradation of these late 
mitotic targets, APC/C(CDH1) ensures disassembly of the components of the 
kinetochore, mitotic spindle, and the cytokinetic furrow before the next cell cycle 
begins [97]. 
In G1, the APC/C plays a critical role in preventing premature S-phase 
entry until pre-replication complexes (pre-RCs) have been assembled at the 
replication origins. To this end, CDK activity is kept low by continued 
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APC/C(CDH1)-mediated cyclin degradation. Additionally, APC/C(CDH1) controls 
CDK activity by targeting FBXL1 (SKP2), an SCF component with several CDKN 
targets [29, 42, 63, 65, 66]. Assembly of the pre-RCs is controlled by 
APC/C(CDH1) by targeting geminin, an inhibitor of pre-RC formation, for 
degradation [2, 73, 90]. When APC/C(CDH1) is inactivated in late G1, geminin is 
stabilized, which ensures against origin re-licensing until the next cell cycle. 
The APC/C is highly regulated, both temporally and in terms of substrate 
targeting. As has been discussed, this regulation is achieved through its 
association with adaptors, like CDC20 and CDH1, binding of APC/C inhibitors, 
like EMI1, and phosphorylation of the APC/C core. Additionally, in mitosis, the 
APC/C is the target of the SAC [4, 22, 28, 52, 98, 99]. 
The APC/C and the SAC 
Equal division of sister chromatids between two daughter cells is an 
inherently dangerous process, as mistakes result in daughter cells with 
chromosomal abnormalities, leading to cell death or cancer. For this reason, 
mitosis is a highly regulated and complex sequence of events. Mitosis is divided 
into four distinct phases: prophase, metaphase, anaphase, and telophase.  
During prophase, chromosomes condense, the nuclear envelope 
disappears, and the mitotic spindle begins to form (Figure 2). The mitotic spindle 
consists of microtubules attached to a microtubule organizing complex called the 
centrosome. Each pair of sister chromatids is joined together at the centromere 
by a protein complex called the kinetochore. During metaphase, microtubule 




Figure 2. Illustration of the mechanism of the SAC. Unattached kinetochores 
activate the SAC and produce an inhibitory signal targeting the APC/C. Proper 
kinetochore attachment, in metaphase, inactivates the SAC, relieving inhibition of 
the APC/C. Active APC/C promotes the metaphase-anaphase transition.  
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kinetochore of each pair of sister chromatids (Figure 2). Microtubule motor 
proteins located near each of the centrosomes pull the microtubules in opposite 
directions, placing tension on kinetochores. Because the sister chromatids are 
still joined at the kinetochore, sister chromatids arrange themselves in the middle 
of the cell, forming a line called the metaphase plate. In anaphase, cleavage of 
cohesins, proteins that hold sister chromatids together, allows each sister 
chromatid to be pulled to opposite ends of the cell by shortening of kinetochore-
associated microtubules (Figure 2). However, before proceeding to anaphase, 
the cell must pass the spindle assembly checkpoint (Figure 2). Microtubule-
targeting drugs, such as paclitaxel, function by exploiting the SAC. By interfering 
with microtubule function, paclitaxel activates the SAC, leading to APC/C 
inhibition, mitotic arrest, and apoptosis in cancer cells. In the absence of spindle 
disruption, the SAC will be satisfied and the cell will progress through anaphase 
to telophase, during which, sister chromatids reach the poles of the cell, nuclear 
envelopes begin to form, and spindle microtubules depolymerize. Following 
telophase is cytokinesis, where the cytosol and its contents are divided into two 
daughter cells, each with a full set of genetic material. 
The SAC is a quality control mechanism that prevents unequal 
segregation of chromatids between two daughter cells. In metaphase, 
chromosomes that are unattached or improperly attached to the mitotic spindle 
promote SAC activation and halt cell division until the mistake can be corrected. 
Even a single unattached kinetochore is sufficient to activate the SAC and 
prevent mitotic exit. One of the first studies to point out this phenomenon was 
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performed by Raymond Zirkle, who noted that metaphase cells will “wait” when 
just one chromosome was retarded [100]. Later studies using microtubule 
depolymerizing agents, such as nocodazole and colchicine, found that the 
metaphase-anaphase transition was delayed in response to inhibition of mitotic 
spindle assembly [101]. Fittingly, the newly discovered mitotic checkpoint was 
designated the spindle-assembly checkpoint. However, the source of the “wait” 
signal was still unclear. To this end, Rieder et. al showed that mitotic exit could 
be accelerated by laser ablation of the last unattached kinetochore, providing 
evidence that the “wait” signal was produced at kinetochores [84]. In the decades 
following these studies, the mechanisms by which the SAC senses unattached 
kinetochores and how it mediates mitotic arrest have become clearer, but many 
unanswered questions remain.  
For the SAC to function, the cell must first be able to detect the status of 
kinetochore attachment and then respond properly. The detection function is 
performed by a sensory system that monitors kinetochore-spindle attachment. In 
response to unattached kinetochores, the sensory system will activate an effector 
system that induces mitotic arrest via APC/C inhibition [85]. The sensory function 
of the SAC begins at kinetochores, multi-subunit complexes that are the interface 
between chromosomes and spindle microtubules [85]. The ‘outer’ layer contains 
an intricate network of three separate complexes: The KNL1 (kinetochore 
scaffold 1) complex, the MIS12 (protein MIS12 homolog) complex, and the 
NDC80 (Kinetochore protein NDC80 Homolog) complex (KMN network). The 
KMN network promotes spindle attachment by interaction with a calponin-
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homology domain on the NDC80 complex, while the ‘inner’ layer binds to 
centromeric chromatin through a histone H3 variant, CENP-A (histone H3-like 
centromeric protein A) [102]. Prior to kinetochore-microtubule attachment, all 
SAC proteins are recruited to kinetochores and, as spindle attachment 
progresses, levels of these proteins decrease [103]. Some evidence suggests 
that kinetochores serve as platforms for assembly of the SAC effector, the mitotic 
checkpoint complex (MCC), but it is still not clear whether full or partial assembly 
of the MCC occurs here. In either case, it is thought that the complete MCC must 
be able to diffuse freely throughout the cell to inhibit the APC/C sufficiently [84, 
85, 103]. Interestingly, it has been found that the SAC does not work like a 
switch, but is able to be activated to different levels [104]. Furthermore, the same 
study found that different microtubule-targeting agents could differentially activate 
the SAC, causing gradations of APC/C inhibition and varying the extent of mitotic 
delay.    
Aurora Kinase B is a serine/threonine kinase that is particularly important 
to SAC function [59]. During mitosis, it is found in high amounts at kinetochores 
[105]. There, it phosphorylates kinetochore proteins until kinetochore-microtubule 
attachment occurs, at which point its activity promptly declines. When active, 
aurora kinase B phosphorylates proteins on both the inner and outer kinetochore, 
including CENP-A and components of the KMN network. A key signaling function 
of aurora kinase B is recruitment of MPS1 (monopolar spindle 1 kinase) to 
kinetochores. MPS1, another kinase and critical SAC signaling molecule, 
phosphorylates KNL1 at several MELT sequences (Met-Glu-Leu-Thr), creating 
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docking sites for additional SAC proteins. These proteins include BUB1 (budding 
uninhibited by benzimidazoles 1), BUB3 (budding uninhibited by benzimidazoles 
3), BUBR1 (budding uninhibited by benzimidazoles 1B; BUB1B), MAD1 (mitotic 
arrest-deficient 1), MAD2 (mitotic arrest-deficient 2), and CDC20, which are 
either components of the MCC or promote assembly of the MCC [59, 85, 105].  
The MCC is composed of three SAC proteins MAD2, BUBR1, and BUB3 
in addition to CDC20. Incomplete kinetochore-microtubule attachment promotes 
the assembly of this complex and its inhibition of the APC/C through formation of 
APC/CCdc20-MCC complexes, while proper chromosome biorientation promotes 
MCC disassembly and APC/C activation. The interplay between the mitotic 
spindle, the SAC, mitotic progression and the APC/C is exceedingly complex, but 
an entire class of drugs exploits these connections, providing therapy for 
numerous diseases. 
Importance of this study 
Mitotic inhibitors are drugs that inhibit the cell cycle in mitosis. There are 
several classes of antimitotics and they are used in the treatment of multiple 
diseases, including viral skin infections, fungal infections, gout, and multiple 
types of cancer. Classes of antimitotic drugs include the taxanes (e.g. paclitaxel, 
docetaxel), vinca alkaloids (e.g. vincristine, vinblastine), colchicine, 
podophyllotoxin, and griseofulvin. Importantly, these drugs all target a single 
protein: tubulin. Through their interaction with tubulin, current antimitotics disrupt 
microtubule dynamics through either stabilization or destabilization of 
microtubules. In mitosis, the disruption of microtubule dynamics prevents proper 
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attachment of kinetochores to mitotic spindle microtubules, leading to SAC 
activation, APC/C inhibition, and mitotic arrest.  
The taxanes are a major class of antimitotics and are commonly used to 
treat lung, ovarian, and breast cancer. Despite their widespread use, there are 
numerous issues concerning these drugs. As with most chemotherapeutic 
agents, the taxanes induce cell death in dividing tissues, not limited to malignant 
tissues. Additionally, taxanes exhibit dose-limiting neurotoxicity due to their 
interference with neuronal microtubule dynamics. A major issue that continues to 
receive significant attention is drug resistant cancers. Tumors frequently become 
resistant to current antimitotics, including the taxanes, by mutations in tubulin or 
SAC proteins. Thus, since all current antimitotics target tubulin, cancers with 
these mutations are resistant to the entire class of drugs. Development of drugs 
that target the regulators of mitosis, such as components of the UPS, will provide 
significant benefits over the current antimitotic drugs. 
There are several examples of drugs that target members of the UPS for 
cancer chemotherapy, including the general proteasome inhibitor, bortezomib, for 
treatment of multiple myeloma and mantle cell lymphoma. While bortezomib has 
a measurable therapeutic index, it inhibits all protein degradation, which can 
cause unwanted cytotoxic effects [34]. In an attempt to reduce the off-target 
effects caused by overall inhibition of protein degradation, some groups have 
developed small molecules to inhibit individual E3 ubiquitin ligases. One example 
is Pevonedistat (MLN4924), an inhibitor of NEDD8-activating enzyme [106]. The 
activity of SCF complexes requires neddylation (addition of a small, ubiquitin-like 
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protein) of cullin subunits. Pevonedistat, by blocking SCF neddylation, serves as 
an SCF inhibitor. Despite increased specificity over bortezomib, phase 1 clinical 
trials with pevonedistat reported only modest activity [107]. Through inhibition of 
all SCF ligases, pevonedistat blocks proteasomal degradation of ~20% of 
proteins. Taking into account the breadth of SCF ubiquitin ligase activity, total 
inhibition of SCF ligases is likely an ineffective approach. Additionally, SCF 
complexes display overlapping substrate specificity due to the nature of targeting 
by F-box proteins. As mentioned previously, the redundancy of F-box substrate-
targeting highlights the impracticality of SCF inhibition for achieving specific 
therapeutic effects.  
This thesis characterizes a new class of antimitotic chemotherapeutics 
targeting the major regulator of cell cycle progression, the anaphase promoting 
complex/cyclosome (APC/C). The strategy differs from traditional approaches, in 
that core structures necessary for intermolecular interactions are targeted. 
As previously mentioned, the APC/C catalytic core contains a cullin 
(ANAPC2) and a zinc RING finger (ANAPC11) subunit [5]. At the inception of this 
project, there were no published structures of the APC/C or its subunits. 
However, crystal structures of proteins homologous to ANAPC11 and ANAPC2 
were available. PDB files 1LDJ for CUL1 (ANAPC2 homologous) and RBX1 
(APC11 homologous) were obtained from the protein database maintained by the 
National Library of Medicine. ClustalW software was used to create alignment 
files, and homology models for ANAPC2 and ANAPC11 were generated with 
Modeller 9v1 [108]. ANAPC2 and ANAPC11 were joined by insightII software by 
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aligning ANAPC11 to RBX1 and ANAPC2 to CUL1. Images of the generated 
homology models were exported from either insightII or Chimera software. 
ANAPC2:ANAPC11 homology models were then used to for in silico docking to 
identify compounds predicted to bind the ANAPC11-binding region of ANAPC2 
(Figure 3A). More recently, the full APC/C structure was determined by cryo-
electron microscopy and added to the protein database. The homology models 
were compared to the published structures for ANAPC2-CTD and 
ANAPC11(protein database file 4UI9) and found to be highly similar (Figure 3B). 
Two sites within the ANAPC11-binding region of ANAPC2 were screened using 
SurflexDock and the ZINC drug-like library, which contained, at the time of 
screening, over 3 million compounds. The results were scored and the top ~50 
candidate compounds were selected for each site. A total of nine compounds, 
four targeting one site and five targeting the other, were ordered for studies. 
From these nine compounds, preliminary data indicate that four are cytotoxic in 
various cancer cell lines. These four hit compounds include three compounds 
classified as amino-2-propanols and one as a triazospiro compound (Figure 3C-
F). The predicted ANAPC2 binding regions for the the amino-2-propanols and 





Figure 3. Models of the ANAPC2:ANAPC11 binding interaction and 
structures of predicted inhibitors. A) Homology models of the C-terminal 
domain (CTD) of ANAPC2 (white) binding ANAPC11 (blue). Regions targeted in 
silico are represented in turquoise and green. B) Published cryo-electron 
microscopy structures of the binding interaction of ANAPC2-CTD (white) and 
ANAPC11 (blue). The lower panels show the structures of four predicted 
inhibitors: C) Compound 3; D) Compound 8; E) Compound 10; F) Compound 11. 
Structures in panel A courtesy of B.F. Taylor and J.O. Trent. Panel B structures 





Based on the role of the APC/C in cell cycle regulation, the overarching 
hypothesis is that compounds predicted to inhibit the APC/C will induce mitotic 
arrest and cell death in malignant cells. In this thesis, the following are 
demonstrated: 1) Hit compounds are cytotoxic in multiple cancer types, including 
lung, ovarian, pancreatic, and melanoma cancers; 2) Hit compounds induce cell 
cycle mitotic or G1-arrest depending on the functionality of the SAC; 3) Hit 
compounds induce apoptosis selectively in malignant cells. This thesis, and 
future work, will provide the groundwork for development of these compounds 
into a novel class of antimitotic chemotherapeutics, which are critically needed 
for treatment of anti-microtubule-resistant tumors. Additionally, these compounds 
will serve as useful tools for studying the mechanisms of mitosis and the APC/C. 
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METHODS AND MATERIALS 
CELL CULTURE 
Cells were cultured at 37°C with 5% CO2 in a humidified incubator. A549 
and A375 cells were cultured in Dulbecco’s Modified Eagle’s Medium (Hyclone, 
Logan, UT) supplemented with 10% fetal bovine serum (Hyclone), 100 U/mL 
penicillin and 10 U/mL streptomycin. A2780/CP70 and H460 cells were cultured 
in RPMI-1640 (Hyclone) supplemented with 10% fetal bovine serum (Hyclone), 
100 U/mL penicillin and 10 U/mL streptomycin. SKOV-3 cells were cultured in 
McCoy’s 5A (Hyclone) supplemented with 10% fetal bovine serum (Hyclone), 
100 U/mL penicillin and 10 U/mL streptomycin. Telomerase-immortalized diploid 
fibroblasts, tGM24 cells, were cultured in Eagle’s MEM containing Earle’s salts 
(GIBCO-BRL) supplemented with 0.1 mM non-essential amino acids, 2 mM L-
glutamine 10% fetal bovine serum (Hyclone), 100 U/mL penicillin and 10 U/mL 
streptomycin. SK-Mel-28 cells were cultured in α-MEM (Hyclone) supplemented 
with 10% fetal bovine serum (Hyclone), 100 U/mL penicillin and 10 U/mL 
streptomycin. HBEC3-KT cells were cultured in Keratinocyte-SFM (GIBCO) 
supplemented with 50 µg/mL bovine pituitary extract, 5 ng/mL recombinant 




Cells were seeded in 96-well plates at 8000 cells/ well (A549, H460) or 
2000 cells/ well (HBEC3-KT) and allowed to attach overnight. Cells were treated 
with seven concentrations of compounds 3 (5-60 µM), 8 (10-100 µM), 10 (5-60 
µM), or 11 (1-20 µM). DMSO (0.1%), paclitaxel (100 nM), and staurosporine (10 
µM) were used as controls. Concentration ranges and treatment times for lead 
compounds were chosen based on prior photomicroscopy studies of cell 
morphology and cell death. Cells were incubated with compounds for 48 h, at 
which point alamarBlue (Bio-Rad, Hercules, CA) was added to each well to 10% 
total volume. Plates were incubated with alamarBlue for 4 h at 37°C and 5% 
CO2. The fluorescence of each well was measured with an excitation wavelength 




COLONY FORMING ASSAYS 
Cells were plated in triplicate 6-well plates at a 100 cells/well (3 wells) or 
500 cells/well (3 wells) and allowed to attach overnight. Cells were then exposed 
to DMSO or compounds at the indicated concentrations dissolved in DMSO (final 
[DMSO] = 0.1%). The time of incubation with compounds varied from 5 to 14 
days between cell lines due to differences in doubling times. Generally, colonies 
become visible when clusters reach 32 cells or more, so ≥5 doublings are 
required to fit the definition of a colony. Following incubation with compounds, 
colonies were fixed and stained with crystal violet. Stained colonies were counted 
and the colony forming efficiency (CFE) was calculated by dividing the number of 
colonies formed by the number of cells plated. These values are then used to 
calculate the colony forming efficiency relative to the DMSO control by the 
following formula:  
Colonies (% control) =
Compound CFE




MITOTIC INDEX ANALYSIS 
Cells were seeded in 6-well plates at 1.5 x 105 cells/ well. After allowing 
cells to attach for 24 h, DMSO, paclitaxel (100 nM), or compounds 3, 8, 10, and 
11 were added directly to the media. Concentration ranges and treatment times 
for lead compounds were chosen based on prior photomicroscopy studies of cell 
morphology and cell death. After 24 h cells were harvested for mitotic index 
determination by trypsinization and combined with media and wash. Cells were 
collected by centrifugation and pellets were resuspended and swollen in 2.5 mL 
hypotonic solution (0.075 M KCl). The suspension was incubated at room 
temperature for 15 min. Next, 0.25 mL fixative solution (3:1 methanol: acetic 
acid) was added, and cells were pelleted by centrifugation. Pellets were 
resuspended in 2.5 mL fixative solution and incubated at room temperature for at 
least 20 min. Cells were pelleted again and resuspended in 2.5 mL fresh fixative 
solution. Aliquots were then dropped onto glass slides, air dried, and stained with 
Wright Giemsa solution. Slides were examined under a microscope for 
determination of mitotic index, mitotic catastrophe, and apoptosis. A minimum of 





Cells were synchronized at G1/S by double thymidine block. Experiments 
were performed with 5 X 105 cells in 6 cm dishes. Cells were plated and allowed 
to attach overnight, followed by incubation with 2 mM thymidine for 20 h. 
Thymidine was removed to allow cells to re-enter the cell cycle by aspirating 
media, washing twice with PBS, and adding fresh media. After 8 h, cells were 
treated with 2 mM thymidine for 16 h. Cells were then allowed to re-enter the cell 
cycle by removing media, washing twice with PBS, and adding fresh media. 
DMSO (0.1%), compounds 3 (10 µM), 8 (40 µM), 10 (10 µM), and 11 (5 µM), or 
nocodazole (100 nM) were added directly to the media 5 h after release from 




Cells were lysed with lysis solution (10 mM Tris-HCl pH 7.4, 1 mM EDTA, 
0.1% sodium dodecyl sulfate, 1 mM phenylmethylsulphonylfluoride, 1 mM 
Na3VO4, and 1X cOmpleteTM Protease Inhibitor Cocktail (Roche, #04693116001, 
Basel, Switzerland)). Lysates were sonicated twice for 2-3 s on ice and 
centrifuged at 13,000 x g for 15 min at 4ºC to remove debris. Total protein 
concentration in supernatant was determined by BCA assay (Pierce, #23225, 
Waltham, MA) using bovine serum albumin as standard. Proteins were loaded 
(20-30 µg/lane) and resolved by sodium dodecylsulfate-polyacrylamide gel 
electrophoresis in 12% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad, 
#4561046, Hercules, CA). Proteins were transferred to nitrocellulose 
membranes, which were stained with Ponceau S (Sigma, St. Louis, MO) to check 
for equal protein loading and transfer. Membranes were blocked in 5% milk in 
TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 2 h at room 
temperature. Membranes were probed with mouse monoclonal antibodies for ß-
actin (Sigma, St. Louis, MO, # A5441, 1:10,000 dilution) and cyclin B (BD 
Transduction Laboratories, Franklin Lakes, NJ, #610219, 1:500 dilution) or rabbit 
monoclonal antibodies for securin (Cell Signaling Technology, Danvers, MA, 
#13445, 1:1000 dilution) and vinculin (Cell Signaling Technology, #13901, 1:1000 
dilution). Secondary antibodies (Cell Signaling Technology, Danvers, MA, anti-
mouse IgG, #7076, 1:3000 dilution or anti-rabbit, #7074, 1:2000 dilution) 
conjugated to horseradish peroxidase were bound to primary antibodies and 
protein bands for ß-actin, cyclin B, securin, and vinculin were detected using 
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enhanced chemiluminescence (ECL) Plus Western Blotting Substrate (Pierce, 
#32123, Waltham, MA). Bands were developed using a ChemiDoc XRS System 







Cells were harvested by trypsinization and fixed in 1 mL of ice-cold 70% 
ethanol overnight at 4°C. Following fixation, cells were centrifuged at 1,500 x g 
and cell pellets were resuspended in 500 µL PBS containing 10 µg/mL propidium 
iodide and 100 U/mL RNase A (Sigma) for 30 min at room temperature. Stained 
cells were analyzed on a FACSCalibur (Becton Dickinson, San Jose CA) using 
doublet discrimination. Propidium iodide fluorescence was collected on FL2 
(585/42 nm) using linear amplification, and at least 20,000 events/ sample were 
analyzed. CellQuest software (Beckton Dickinson) was used for data collection 
and Modfit software (Verity Software House, inc., Topsham ME) was used for 





Apoptosis was measured using the Apo-ONE® Homogeneous Caspase-
3/7 Assay from Promega. This assay utilizes a pro-fluorescent caspase-3/7 
substrate that is converted to a highly fluorescent molecule upon cleavage by 
caspase-3/7. Caspase-3/7 activity, and therefore apoptosis, is directly correlated 
to the amount of fluorescence detected. Cells were grown at either 7500 cells/ 
well (A2780/CP70) or 3000 cells/ well (SKOV-3, tGM24) in 96-well plates in 100 
µL media for 24 h. A549, H460, and HBEC3-KT cells were treated with DMSO 
(0.1%), compounds 3 (5-60 µM), 8 (10-80 µM), 10 (1-25 µM), and 11 (1-15 µM). 
A2780/CP70 cells were treated with DMSO (0.1%), compounds 8 (20-80 µM), 10 
(1-20 µM), and 11 (1-20 µM), or paclitaxel (100 nM). SKOV-3 and tGM24 cells 
were treated with DMSO (0.1%), compounds 8 (10-60 µM), 10 (1-10 µM), and 11 
(1-10 µM), or paclitaxel (100 nM). Cells were incubated for 24 h (A2780/CP70, 
SKOV-3), 36 h (A549, H460, HBEC3-KT), or 48 h (tGM24). Concentration ranges 
and treatment times for lead compounds were chosen based on prior 
photomicroscopy studies for induction of apoptosis. Cells were exposed to Apo-
ONE® Caspase-3/7 Reagent (Promega, Madison, WI) by adding 100 µL to each 
well. Contents of the wells were gently mixed using a plate shaker at 300-500 
rpm, and cells were incubated for an additional 1 h, prior to fluorescence 
measurement. The fluorescence of each well was then measured using 499 nm 





ALAMARBLUE SCREENING IN MULTIPLE CELL TYPES 
The purpose of this part of the study was to perform initial screening of 
candidate compounds for cytotoxic properties. Compounds were initially 
screened by alamarBlue assays. These assays are similar to tetrazolium dye-
based MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays 
in that they both utilize reporter dyes to measure the reductive capacity, and, 
therefore, the metabolic activity, of the cell. Additionally, both assays allow rapid 
screening of multiple compounds. AlamarBlue differs in that it can be added 
directly to the cell culture media, unlike MTT, which requires washing steps. 
Inhibition of the APC/C is predicted to cause mitotic arrest, so the wash steps 
with MTT assays may result in the loss of these loosely-attached cells. Thus, 
alamarBlue was used because it allows for the measurement of cells in any cell 
cycle phase. Several predicted APC/C inhibitors (3, 10, and 11) were found to 
reduce viability effectively in multiple cell lines representing malignant and non-
malignant lung tissues (Figure 4). While these assays indicate that compounds 
have no therapeutic window, further investigations are necessary to determine if 




Figure 4. Hit compounds reduce viability in lung cell lines. AlamarBlue 
assays were performed with compounds 3, 8, 10, and 11 in A549 and H460, 
malignant lung cell lines, and HBEC3-KT, non-malignant lung cells. Cells were 
exposed to compounds 3, 8, 10, and 11 at the indicated concentrations for 48 h.  
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COLONY FORMING ASSAYS IN MULTIPLE CELL TYPES 
AlamarBlue assays don’t distinguish between cytostasis and reduced 
viability. While alamarBlue assays are a useful tool for screening, they are not a 
true measure of inhibition of replicative ability. To confirm the results of the 
alamarBlue viability date, colony forming assays, which provide a direct measure 
of the effect compounds have on replicative capacity, were performed. The 
results of colony forming assays were consistent with the alamarBlue data, 
indicating that compounds 3, 8, 10, and 11 dose-dependently reduce colony 
formation (Figure 5). Compounds effectively reduced colony formation in cell 
lines representing malignant lung, ovarian, pancreatic, and melanoma tissues. 
Compounds also reduced colony formation in HBEC3-KT, non-malignant lung 
cells, and tGM24, telomerase-immortalized diploid fibroblasts. These non-
malignant cells, however, were found to be alive and attached to the plate, but 
had not divided to form colonies (Figure 6). The observation that compounds are 
cytotoxic to malignant cells, but cytostatic in non-malignant cells provides 
evidence for a therapeutic window. Interestingly, when compared to DMSO-
treated cells, HBEC3-KT cells exposed to hit compounds appear much smaller, 
suggesting that compounds interfere with pathways regulating cell growth and 
metabolism. Therefore, it will be necessary to investigate these pathways as 






Figure 5. Hit compounds reduce colony forming ability of multiple lung, 
ovarian, pancreatic, and melanoma cell lines. Colony forming assays 
performed in lung (top row), ovarian and fibroblasts (second row), pancreatic 
(third row), and melanoma (fourth row) cell lines. Lung cell lines (A549, H460, 
HBEC3-KT) were treated with compounds 3, 8, 10, and 11 at the indicated 
concentrations. Ovarian cell lines (A2780/CP70, SKOV-3) and fibroblasts 
(tGM24) were treated with compounds 8, 10, and 11 at the indicated 
concentrations (data courtesy of Doug Saforo). Pancreatic (MIAPACA2, PANC1, 
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S2VP10) and melanoma (SK-MEL-28, A375) cell lines were treated with 
compounds 3, 8, 10, and 11 (data courtesy of Brian Sils).  
 
Figure 6. Compounds cause cytostasis in non-malignant lung cells. Phase 
contrast photomicrographs of HBEC3-KT cells stained with crystal violet following 
exposure to A) compound 3 (20 µM), B) compound 8 (20 µM), C) compound 10 




MITOTIC INDEX ANALYSIS OF MULTIPLE CELL TYPES 
The cytotoxicity of several hit compounds has been demonstrated, but it is 
possible that this toxicity could be due to off target effects. These compounds are 
predicted to inhibit the APC/C, which is essential for mitotic progression, 
particularly the metaphase-anaphase transition. Thus, an increase in the mitotic 
index in cells exposed to these compounds would be consistent with APC/C 
inhibition. Therefore, mitotic index analyses were performed to determine the 
effect of compounds. The results of these experiments indicate that compounds 
3, 8, 10, and 11 significantly increase mitotic index compared to DMSO controls 
(Figure 7). Compounds increased mitotic index in multiple cell types, including 
malignant and non-malignant lung and ovarian cells (Figure 7). However, these 
results and the results of colony forming assays indicate that non-malignant cells 
are able to survive mitotic arrest induced by these compounds, while malignant 




Figure 7. Lung, ovarian, and fibroblast cells exposed to hit compounds 
have increased populations in mitosis. Mitotic indices determined in lung (A-
C), ovarian (D, E) and telomerase-immortalized diploid skin fibroblasts (F). Lung 
cell lines A549 (A), H460 (B), and HBEC3-KT (C) were treated with Taxol (100 
nM) and compounds 3 (10 µM), 8 (60 µM), 10 (10 µM), and 11 (5 µM). 
Treatments for A2780/CP70 (D) were Taxol (10 nM) and compounds 8 (5 µM), 
10 (0.4 µM), and 11 (0.4 µM). SKOV-3 (E) were treated with Taxol (50 nM) and 
compounds 8 (20 µM), 10 (1 µM), and 11 (1 µM). tGM24 (F) cells were treated 
with Taxol (50 nM) and compounds 8 (20 µM), 10 (1 µM), and 11 (1 µM). Percent 




STABILITY OF APC/C SUBSTRATES IN SYNCHRONIZED A375 CELLS 
The APC/C is essential for mitotic progression, particularly the 
metaphase-anaphase transition. Non-functional APC/C will be unable to target its 
substrates for ubiquitinylation and degradation. These substrates include cyclin 
B, whose degradation is required for mitotic exit, and securin, which must be 
degraded to allow anaphase progression. As a counterpoint, inhibition of the 
APC/C does not necessarily result in stabilization of its substrates. For example, 
proteolysis of APC/C(CDC20) substrate cyclin A was not delayed in the presence 
of active SAC in vitro [109]. Additionally, NEK2A (never in mitosis gene a-related 
kinase 2), has been shown to be targeted by APC/C(CDC20) independent of 
SAC activation [110]. Furthermore, some cancers with weakened checkpoints 
may undergo “mitotic slippage,” whereby cells slowly degrade cyclin B and 
prematurely exit mitosis due to incomplete APC/C inhibition [111, 112]. While 
there is no evidence suggesting that cyclin B or securin can be degraded when 
the APC/C is completely inhibited, these studies highlight the complex nature of 
APC/C regulation and activity. Inhibition of the APC/C is most likely to cause cell 
cycle arrest in mitosis. However, the APC/C also contributes to progression 
through G1-phase of the cell cycle [2, 27]. Thus, it is possible that APC/C 
inhibition may result in G1-arrest, or both G1- and mitotic-arrest. 
To provide further evidence that hit compounds target the APC/C and 
characterize the mechanism of cell cycle arrest, the kinetics of cyclin B and 
securin degradation in synchronized A375 cells were analyzed. Synchronization 
of cultures was performed because it is possible that hit compounds targeting the 
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APC/C may not inhibit the total APC/C population. Incomplete inhibition of the 
APC/C would allow slow degradation of its target proteins, resulting in mitotic 
delay, similar to mitotic slippage by weakened checkpoints, not mitotic arrest. 
While mitotic progression may be slowed, the population of mitotic cells is likely 
to be low at any certain time. Therefore, if hit compounds do not completely 
inhibit APC/C activity, their effects may be masked in asynchronous cultures. To 
increase the likelihood of obtaining highly synchronous cultures, A375 cells were 
chosen, because they have a short doubling time. Following G1/S blockade, 
synchronized cells were allowed to re-enter the cell cycle for 5 h before adding 
compounds. After addition of compounds, APC/C targets, securin and cyclin B, 
were measured every hour for 7 h by western blot (Figure 8). In DMSO-treated 
cells, cyclin B and securin levels steadily increase from 6-9 h after release, 
followed by a sharp decline from 10-12 h, indicating that these cells are exiting 
mitosis between 9 and 10 h after G1/S. Nocodazole is commonly used to arrest 
cells in mitosis during prometaphase. Consistent with mitotic arrest, the levels of 
cyclin B and securin in nocodazole-treated cells remained elevated through 12 h 
after G1/S, our final timepoint. Compounds 3, 8, 10, and 11 had variable effects 
on cyclin B and securin levels. Similar to nocodazole, compound 3 completely 
stabilized cyclin B and delayed securin degradation until 12 h after G1/S, 
consistent with APC/C inhibition and mitotic arrest. Conversely, compound 8 had 
no effect on cyclin B levels, when compared to DMSO, but securin was 
stabilized. Cells treated with compounds 10 and 11 displayed delayed kinetics of 
degradation for both cyclin B and securin. In these cells, cyclin B and securin 
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levels began to decline after 9 h, but the rate of decline was slowed in 
comparison to DMSO. These delayed kinetics of degradation suggest 
compounds 10 and 11 cause partial inhibition of the APC/C, leading to mitotic 




Figure 8. APC/C mitotic targets display extended kinetics of degradation 
when exposed to hit compounds. Western blot time course analysis of cyclin B 
and securin in synchronized A375 cells treated with compounds 3 (10 µM), 8 (40 
µM), 10 (10 µM), and 11 (4 µM). DMSO and nocodazole (100 nM) were used as 




CELL CYCLE EFFECTS OF HIT COMPOUNDS IN A SAC-DEFICIENT 
MELANOMA CELL LINE 
As detailed previously, resistance to microtubule-targeting 
chemotherapeutics is a major issue. Many cases of resistance result from 
mutations in SAC proteins [113]. These mutations lead to SAC-deficient cancers, 
which are not arrested in mitosis in response to disruption of microtubule 
dynamics. Recent studies have focused on the development of drugs targeting 
the proteins that regulate the mitotic spindle, including the motor protein Kinesin-
5, Aurora kinases, and Polo-like kinases. While these drugs are less neurotoxic 
than taxanes, their efficacy is no better or worse against solid tumors [111]. 
Targeting the master regulator of mitosis, the APC/C, addresses these issues. 
The APC/C is essential to cell proliferation and mutations causing dysfunctional 
APC/C result in non-viable cells [99, 114]. Therefore, unlike SAC inactivation, 
which promotes resistance, APC/C inactivating mutations should be fatal. In 
SAC-proficient cells, unattached kinetochores cause mitotic arrest through SAC 
activation, but the downstream target of the SAC is the APC/C. Therefore, SAC-
deficient cells should arrest in mitosis in response to APC/C inhibition because 
compounds targeting the APC/C bypass the need for a functional SAC. 
To examine the effects of hit compounds in SAC-deficient cells, several 
experiments were performed in SK-MEL-28 cells, which are resistant to 
paclitaxel-induced mitotic arrest (Figure 9). To examine cytotoxicity of hit 
compounds in this cell line, colony forming assays were performed with 




Figure 9. Compounds targeting distinct, overlapping regions of ANAPC2 
induce cell cycle arrest at different points in SAC-deficient melanoma cells. 
A) Colony forming assays with SK-MEL-28 cells exposed to the indicated 
concentrations of compounds 3, 3a1, and 8. B) Quantitation of mitoses, mitotic 
catastrophes, and apoptosis by 20 µM compounds 3, 3a1, and 8. C) Histograms 
from flow cytometry of propidium iodide-stained cells exposed to 20 µM 
compounds 3, 3a1, and 8 for 24 h. D) Quantitation of data in panel C (# = p<0.05 
vs. DMSO). Data courtesy of Brian Sils and Shuchismita Satpathy.  
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 dose-dependently reduced colony formation. Mitotic index analysis revealed that 
compounds 3 and 3a1 increased the population of mitotic cells, but the mitotic 
index of cells treated with compound 8 was not changed (Figure 9B). Cell cycle 
analysis by propidium iodide staining and flow cytometry indicate that 
compounds 3 and 3a1 increased the population of cells in the G2/M 
compartment and decreased the population in G1/S, correspondingly (Figure 9C, 
top right panel, lower left panel). Interestingly, exposing cells to compound 8 had 
the opposite effect, with an increase in the G1/S compartment and a 
corresponding decrease in the G2/M (Figure 9C, lower right panel). The cause of 
this difference in cell cycle distribution induced by compounds 3 and 3a1 vs. 




APOPTOSIS ASSAYS IN LUNG AND OVARIAN CELL LINES 
 Hit compounds induced mitotic arrest and cell death in multiple cancer cell 
types. The mechanism of cell death is unclear, but the prediction is that 
compounds induce apoptosis in cancer cells. To investigate the mechanism of 
cell death induced by hit compounds, apoptosis assays were performed to detect 
active caspase-3/7, a common marker of apoptosis. Malignant lung cells treated 
with compounds 3, 8, 10 & 11 and ovarian cell lines treated with compounds 8, 
10 &11 displayed increased activation of apoptosis (Figure 10A, B, D, E). In 
contrast, non-malignant HBEC3-KT lung cells and tGM24 diploid skin fibroblast 
cells, showed no increase in caspase-3/7 activity, and, therefore, no apoptosis 
activation, when exposed to compounds 3, 8, 10 & 11 (Figure 10C, F). This result 
is consistent with the cytostatic effect of compounds in non-malignant cells 





Figure 10. Levels of active caspase-3/7 are elevated in lung and ovarian 
cancer cells following exposure to hit compounds. Apoptosis assays were 
performed with compounds 8, 10, and 11 in SKOV-3 and A2780/CP70 ovarian 
cancer cells, and tGM24 telomerase-immortalized fibroblasts.  Ovarian cells were 
exposed to compounds 8, 10, and 11 for 24 h at the indicated concentrations 
before caspase-3/7 activity was measured. Fibroblast cells were exposed to 
compounds 8, 10, and 11 for 48 h at the indicated concentrations before 




Mitotic inhibitors are critical tools in the treatment of cancer. Recently, 
however, numerous issues concerning current microtubule-targeting antimitotics, 
have received increased attention. Arguably the most significant issue with anti-
microtubule drugs is the development of resistant tumors through mutations in 
SAC proteins. Currently, the only approved antimitotic agents target tubulin, 
meaning that resistant tumors are resistant to all antimitotic drugs. The work 
described in this thesis is significant because it provides evidence that targeting 
the proteins that regulate mitotic progression, namely the APC/C, is a strategy 
with numerous potential benefits over microtubule-targeting drugs. Chief among 
these benefits is the fact that targeting the APC/C bypasses the need for a 
functional SAC, meaning that compounds inhibiting the APC/C should be 
effective in tumors resistant to current antimitotics. The APC/C is crucial for the 
metaphase-anaphase transition, but also plays significant roles in mitotic exit and 
G1 progression. The fact that the APC/C regulates multiple points in the cell 
cycle should increase the likelihood that APC/C inhibition will cause cell cycle 
arrest. This hypothesis is supported by results of studies with paclitaxel-resistant 
melanoma cells (Figure 9). Taken together, the data reported in this thesis 
provide evidence that further research and development of compounds targeting 
the APC/C will lead to a valuable new class of antimitotic agents for cancer 
treatment and for research into APC/C function.  
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AlamarBlue, combined with colony forming data, demonstrates that hit 
compounds reduce the replicative ability of multiple cancer types, including lung, 
ovarian, pancreatic, and melanoma. This finding is consistent with the prediction 
that compounds inhibit the APC/C, leading to mitotic arrest and cell death. The 
same assays performed in SAC-deficient cells showed that the APC/C is a 
suitable target for the treatment of paclitaxel-resistant cancers. There was a 
general trend in the effective concentrations of these compounds, with compound 
11 killing cells at the lowest concentrations, followed sequentially by compounds 
10, 3, and 8. However, compounds 3, 8, and 10 have a broader therapeutic 
window, as evidenced by colony forming assays and apoptosis assays, 
suggesting further development will allow improved efficacies and selectivity. 
Mitotic index analysis of hit compounds in the same cell lines revealed 
significant increases in the population of mitotic cells, compared to DMSO. 
Generally, mitotic index was much greater in cells treated with paclitaxel than 
with hit compounds. However, direct comparisons between the efficacy of hit 
compounds and paclitaxel are not useful, at this early stage of development. 
These hit compounds contain several structural features that will allow the 
synthesis of analog libraries for structure-activity relationship studies (SAR) to 
improve efficacy. 
This work also demonstrates that, to varying degrees, candidate 
compounds stabilize or delay the degradation of two APC/C substrates that are 
key to mitotic progression: cyclin B and securin. Interestingly, exposure to either 
compound 3 or compound 8 resulted in the opposite pattern of cyclin B and 
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securin stabilization. Compound 3 completely stabilized cyclin B and delayed 
securin degradation, consistent with mitotic arrest and APC/C inhibition. 
Compound 8 had no effect on cyclin B, but appeared to slow the kinetics of 
securin degradation. Degradation of securin is required for activation of separase 
and cleavage of cohesins, so this result suggests that cells treated with 
compound 8 may be exiting mitosis into a pseudo-G1 state, in which cells contain 
2C DNA content. Several studies have demonstrated other mechanisms by 
which securin levels can be reduced, indicating that total APC/C inhibition may 
not result in full stabilization. Extended mitotic arrest can lead to mitotic 
catastrophe, a type of mitosis-linked cell death in response to chromosomal 
damage, and some have found that DNA damage can cause decreased 
expression of securin via TP53-mediated repression [115]. Therefore, if 
compounds cause extended mitotic arrest and mitotic catastrophe, as observed 
in ovarian cancer cells shown in Figure 6, total stabilization of securin may not 
occur. Additionally, UV radiation can cause mitotic arrest and catastrophe, and 
was found to lead to degradation of securin mediated by an SCF complex 
(SKP1-CUL1-βTrCP) [54]. The phosphorylated, mitotic form of securin has also 
been found to be a target for SCF-mediated degradation [55]. These redundant 
mechanisms for the degradation of securin may account for some of the 
differences seen in its pattern of degradation. Further complicating matters, the 
APC/C and SCF complexes are highly similar and the homology models were 
generated using published structures of the SCF. Therefore, it is possible that 
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compounds may be targeting one or the other or both complexes, a factor that 
complicates interpretations of these data.  
Importantly, candidate compounds were determined to be effective in 
SAC-deficient, paclitaxel-resistant SK-MEL-28 cells. These cells, interestingly, 
were arrested at different cell cycle stages when exposed to either compound 3 
or compound 8. The mechanism to account for this difference is still unclear. 
However, one possibility is differences in the predicted ANAPC2 binding 




Figure 11. Two regions of ANAPC2 targeted in silico and predicted binding 
interactions of compounds 3 and 8. A) Homology models of the C-terminal 
domain of ANAPC2 (white) and ANAPC11 (blue) showing two regions of the 
ANAPC11-binding domain of ANAPC2 that were targeted in silico (turquoise, 
green). B) Predicted binding interaction of compound 3 with ANAPC2 (white) in 
its ANAPC11 (blue) binding domain. C) Predicted binding interaction of 
compound 8 with ANAPC2 (white) in its ANAPC11 (blue) binding domain. D) 
Overlay of the predicted binding interactions of compounds 3 (red) and 8 
(turquoise) with ANAPC2 (white).  
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Compound 3 is a triazospiro-containing compound, while compound 8 contains 
an amino-2-propanol structure. The two compounds are predicted to target 
distinct but overlapping sites at the ANAPC11-binding region of ANAPC2 (Figure 
11B-D). It is possible that one or both compounds, rather than preventing binding 
of ANAPC11, alter the binding interaction. Changing the binding interaction could 
lead to altered, rather than inhibited, activity of the APC/C, increasing or 
decreasing its ability to ubiquitinylate certain substrates, leading to arrest in either 
mitosis or G1, depending on the effect. As mentioned previously, we cannot yet 
rule out the possibility that compounds inhibit SCF complexes and not the 
APC/C. Therefore, it is possible that these two compounds interact differently 
with these two E3s, leading to the observed differences in cell cycle distribution.  
The activity of these compounds in SAC-deficient cells is an exciting 
finding, as it suggests further development may result in a class of drugs that can 




A major issue concerning the future of this project is demonstration that 
compounds are specifically targeting the APC/C. While much of the data are 
consistent with APC/C inhibition, there are other explanations for the effects of 
these compounds, such as interactions with the CUL1 and RBX1 subunits of 
SCF complexes. Future studies will be required to demonstrate the specificity of 
these compounds for the APC/C. Direct binding of compounds to ANAPC2 could 
be demonstrated using recombinant ANAPC2 and ANAPC11 for in vitro binding 
reactions with hit compounds. However, inhibition of ANAPC2:ANAPC11 
complex formation could also be demonstrated in cells treated with compounds 
by immunoprecipitation of one or the other, followed by western blots to detect 
the presence of its binding partner. In addition to showing that compounds 
prevent ANAPC2:ANAPC11 binding, it is also necessary to demonstrate that 
they inhibit the catalytic activity. APC/C inhibition should result in decreased 
ubiquitinylation of its substrates. However, previous work has shown, however, 
that only ANAPC11, not ANAPC2, is required for ubiquitinylation of cyclin B 
[108]. Others have shown that ubiquitinylation of cyclin B can be catalyzed in the 
presence of Zn2+ and an E2 enzyme [23]. Thus, preventing the association of 
rAPC11 with rAPC2 is not expected to totally abrogate cyclin B ubiquitinylation. 
To demonstrate inhibition of securin ubiquitinylation in vitro, reactions can be 
performed using recombinant ANAPC2, ANAPC11, UBE2C, and an E1 enzyme. 
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Like the binding reactions, inhibition of ubiquitinylation can also be shown with 
cells in culture by immunoprecipitating securin, following exposure to 
compounds.  
This study provides evidence for compound-induced stabilization of 
APC/C mitotic substrates in one melanoma cell line. Future work will involve 
further characterization of the effects on APC/C substrates in other cancer types, 
such as the lung, ovarian, and pancreatic cells used in this study. In addition to 
analysis in other cell lines, future studies will examine how compounds affect the 
stability of APC/C targets in G1, such as geminin, FOXM1, and CDH1. These G1 
target proteins are likely stabilized in SAC-deficient cells, such as SK-MEL-28 
melanoma cells. 
Further work using SAC-deficient cancers is also necessary if compounds 
are to be demonstrated as a viable alternative to microtubule-targeting drugs. In 
addition to cell lines which have developed resistance to these drugs by natural 
means, compounds will be tested in cells that have the SAC knocked-down by 
siRNA.  
Additionally, developing these compounds into drug-like molecules will 
require further SAR studies. Finally, In vivo animal studies will be necessary to 





1. Murray, A.W., Recycling the cell cycle: cyclins revisited. Cell, 2004. 116(2): p. 
221-34. 
2. Diffley, J.F., Regulation of early events in chromosome replication. Curr Biol, 
2004. 14(18): p. R778-86. 
3. Fung, T.K. and R.Y. Poon, A roller coaster ride with the mitotic cyclins. Semin 
Cell Dev Biol, 2005. 16(3): p. 335-42. 
4. Teixeira, L.K. and S.I. Reed, Ubiquitin ligases and cell cycle control. Annu Rev 
Biochem, 2013. 82: p. 387-414. 
5. Glotzer, M., A.W. Murray, and M.W. Kirschner, Cyclin is degraded by the 
ubiquitin pathway. Nature, 1991. 349(6305): p. 132-8. 
6. Komander, D. and M. Rape, The ubiquitin code. Annu Rev Biochem, 2012. 81: p. 
203-29. 
7. Hershko, A. and A. Ciechanover, The ubiquitin system. Annu Rev Biochem, 
1998. 67: p. 425-79. 
8. Hibbert, R.G., et al., E3 ligase Rad18 promotes monoubiquitination rather than 
ubiquitin chain formation by E2 enzyme Rad6. Proc Natl Acad Sci U S A, 2011. 
108(14): p. 5590-5. 
9. Dimova, N.V., et al., APC/C-mediated multiple monoubiquitylation provides an 
alternative degradation signal for cyclin B1. Nat Cell Biol, 2012. 14(2): p. 168-76. 
10. King, R.W., et al., How proteolysis drives the cell cycle. Science, 1996. 
274(5293): p. 1652-9. 
11. Rieser, E., S.M. Cordier, and H. Walczak, Linear ubiquitination: a newly 
discovered regulator of cell signalling. Trends Biochem Sci, 2013. 38(2): p. 94-
102. 
12. Wang, H., et al., Role of histone H2A ubiquitination in Polycomb silencing. 
Nature, 2004. 431(7010): p. 873-8. 
13. Kumar, Y., V. Radha, and G. Swarup, Interaction with Sug1 enables Ipaf 
ubiquitination leading to caspase 8 activation and cell death. Biochem J, 2010. 
427(1): p. 91-104. 
14. Boname, J.M., et al., Efficient internalization of MHC I requires lysine-11 and 
lysine-63 mixed linkage polyubiquitin chains. Traffic, 2010. 11(2): p. 210-20. 
15. Yang, W.L., et al., The E3 ligase TRAF6 regulates Akt ubiquitination and 
activation. Science, 2009. 325(5944): p. 1134-8. 
16. Kulathu, Y. and D. Komander, Atypical ubiquitylation - the unexplored world of 
polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol, 2012. 
13(8): p. 508-23. 
17. Asher, G., N. Reuven, and Y. Shaul, 20S proteasomes and protein degradation 
"by default". Bioessays, 2006. 28(8): p. 844-9. 
18. Rape, M. and S. Jentsch, Taking a bite: proteasomal protein processing. Nat Cell 
Biol, 2002. 4(5): p. E113-6. 
19. Schulman, B.A. and J.W. Harper, Ubiquitin-like protein activation by E1 enzymes: 
the apex for downstream signalling pathways. Nat Rev Mol Cell Biol, 2009. 10(5): 
p. 319-31. 
20. Markson, G., et al., Analysis of the human E2 ubiquitin conjugating enzyme 
protein interaction network. Genome Res, 2009. 19(10): p. 1905-11. 
21. Nakayama, K.I. and K. Nakayama, Ubiquitin ligases: cell-cycle control and 
cancer. Nat Rev Cancer, 2006. 6(5): p. 369-81. 
22. Zhao, Y. and Y. Sun, Cullin-RING Ligases as attractive anti-cancer targets. Curr 
Pharm Des, 2013. 19(18): p. 3215-25. 
62 
 
23. Tang, Z., et al., APC2 Cullin protein and APC11 RING protein comprise the 
minimal ubiquitin ligase module of the anaphase-promoting complex. Mol Biol 
Cell, 2001. 12(12): p. 3839-51. 
24. Kapanidou, M., N.L. Curtis, and V.M. Bolanos-Garcia, Cdc20: At the Crossroads 
between Chromosome Segregation and Mitotic Exit. Trends Biochem Sci, 2017. 
25. Kraft, C., et al., The WD40 propeller domain of Cdh1 functions as a destruction 
box receptor for APC/C substrates. Mol Cell, 2005. 18(5): p. 543-53. 
26. Petroski, M.D. and R.J. Deshaies, Mechanism of lysine 48-linked ubiquitin-chain 
synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. Cell, 2005. 
123(6): p. 1107-20. 
27. Rape, M. and M.W. Kirschner, Autonomous regulation of the anaphase-
promoting complex couples mitosis to S-phase entry. Nature, 2004. 432(7017): 
p. 588-95. 
28. Yamaguchi, M., et al., Cryo-EM of Mitotic Checkpoint Complex-Bound APC/C 
Reveals Reciprocal and Conformational Regulation of Ubiquitin Ligation. Mol 
Cell, 2016. 63(4): p. 593-607. 
29. Wei, W., et al., Degradation of the SCF component Skp2 in cell-cycle phase G1 
by the anaphase-promoting complex. Nature, 2004. 428(6979): p. 194-8. 
30. Wang, R., J.L. Burton, and M.J. Solomon, Transcriptional and post-transcriptional 
regulation of Cdc20 during the spindle assembly checkpoint in S. cerevisiae. Cell 
Signal, 2017. 33: p. 41-48. 
31. Wei, R., et al., Deubiquitinases in cancer. Oncotarget, 2015. 6(15): p. 12872-89. 
32. Huang, X., et al., Deubiquitinase USP37 is activated by CDK2 to antagonize 
APC(CDH1) and promote S phase entry. Mol Cell, 2011. 42(4): p. 511-23. 
33. Vodermaier, H.C., APC/C and SCF: controlling each other and the cell cycle. 
Curr Biol, 2004. 14(18): p. R787-96. 
34. Jia, L. and Y. Sun, SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer 
Drug Targets, 2011. 11(3): p. 347-56. 
35. Eldridge, A.G. and T. O'Brien, Therapeutic strategies within the ubiquitin 
proteasome system. Cell Death Differ, 2010. 17(1): p. 4-13. 
36. Varshavsky, A., The ubiquitin system, an immense realm. Annu Rev Biochem, 
2012. 81: p. 167-76. 
37. Zheng, N., Z. Wang, and W. Wei, Ubiquitination-mediated degradation of cell 
cycle-related proteins by F-box proteins. Int J Biochem Cell Biol, 2016. 73: p. 99-
110. 
38. Frescas, D. and M. Pagano, Deregulated proteolysis by the F-box proteins SKP2 
and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer, 2008. 8(6): p. 438-
49. 
39. Welcker, M. and B.E. Clurman, FBW7 ubiquitin ligase: a tumour suppressor at 
the crossroads of cell division, growth and differentiation. Nat Rev Cancer, 2008. 
8(2): p. 83-93. 
40. Peters, J.M., The anaphase promoting complex/cyclosome: a machine designed 
to destroy. Nat Rev Mol Cell Biol, 2006. 7(9): p. 644-56. 
41. Peters, J.M., Emi1 proteolysis: how SCF(beta-Trcp1) helps to activate the 
anaphase-promoting complex. Mol Cell, 2003. 11(6): p. 1420-1. 
42. Bashir, T., et al., Control of the SCF(Skp2-Cks1) ubiquitin ligase by the 
APC/C(Cdh1) ubiquitin ligase. Nature, 2004. 428(6979): p. 190-3. 
43. Watanabe, N., et al., M-phase kinases induce phospho-dependent ubiquitination 




44. Habedanck, R., et al., The Polo kinase Plk4 functions in centriole duplication. Nat 
Cell Biol, 2005. 7(11): p. 1140-6. 
45. Cunha-Ferreira, I., et al., The SCF/Slimb ubiquitin ligase limits centrosome 
amplification through degradation of SAK/PLK4. Curr Biol, 2009. 19(1): p. 43-9. 
46. Guderian, G., et al., Plk4 trans-autophosphorylation regulates centriole number 
by controlling betaTrCP-mediated degradation. J Cell Sci, 2010. 123(Pt 13): p. 
2163-9. 
47. Buschhorn, B.A. and J.M. Peters, How APC/C orders destruction. Nat Cell Biol, 
2006. 8(3): p. 209-11. 
48. Lu, D., et al., Multiple mechanisms determine the order of APC/C substrate 
degradation in mitosis. J Cell Biol, 2014. 207(1): p. 23-39. 
49. Agarwal, R. and O. Cohen-Fix, Phosphorylation of the mitotic regulator 
Pds1/securin by Cdc28 is required for efficient nuclear localization of 
Esp1/separase. Genes Dev, 2002. 16(11): p. 1371-82. 
50. Rape, M., S.K. Reddy, and M.W. Kirschner, The processivity of 
multiubiquitination by the APC determines the order of substrate degradation. 
Cell, 2006. 124(1): p. 89-103. 
51. Williamson, A., et al., Regulation of ubiquitin chain initiation to control the timing 
of substrate degradation. Mol Cell, 2011. 42(6): p. 744-57. 
52. Lindon, C., Control of mitotic exit and cytokinesis by the APC/C. Biochem Soc 
Trans, 2008. 36(Pt 3): p. 405-10. 
53. Castro, A., et al., The anaphase-promoting complex: a key factor in the 
regulation of cell cycle. Oncogene, 2005. 24(3): p. 314-25. 
54. Limon-Mortes, M.C., et al., UV-induced degradation of securin is mediated by 
SKP1-CUL1-beta TrCP E3 ubiquitin ligase. J Cell Sci, 2008. 121(11): p. 1825-31. 
55. Gil-Bernabe, A.M., et al., Protein phosphatase 2A stabilizes human securin, 
whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell 
Biol, 2006. 26(11): p. 4017-27. 
56. Busino, L., et al., Degradation of Cdc25A by beta-TrCP during S phase and in 
response to DNA damage. Nature, 2003. 426(6962): p. 87-91. 
57. Jin, J., et al., SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A 
protein phosphatase. Genes Dev, 2003. 17(24): p. 3062-74. 
58. Minella, A.C., et al., p53 and SCFFbw7 cooperatively restrain cyclin E-associated 
genome instability. Oncogene, 2007. 26(48): p. 6948-53. 
59. Welburn, J.P., et al., Aurora B phosphorylates spatially distinct targets to 
differentially regulate the kinetochore-microtubule interface. Mol Cell, 2010. 
38(3): p. 383-92. 
60. Taylor, S. and J.M. Peters, Polo and Aurora kinases: lessons derived from 
chemical biology. Curr Opin Cell Biol, 2008. 20(1): p. 77-84. 
61. Kwon, Y.W., et al., Pten regulates Aurora-A and cooperates with Fbxw7 in 
modulating radiation-induced tumor development. Mol Cancer Res, 2012. 10(6): 
p. 834-44. 
62. Teng, C.L., et al., FBXW7 is involved in Aurora B degradation. Cell Cycle, 2012. 
11(21): p. 4059-68. 
63. Nakayama, K.I., S. Hatakeyama, and K. Nakayama, Regulation of the cell cycle 
at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys 
Res Commun, 2001. 282(4): p. 853-60. 
64. Malek, N.P., et al., A mouse knock-in model exposes sequential proteolytic 




65. Bornstein, G., et al., Role of the SCFSkp2 ubiquitin ligase in the degradation of 
p21Cip1 in S phase. J Biol Chem, 2003. 278(28): p. 25752-7. 
66. Yu, Z.K., J.L. Gervais, and H. Zhang, Human CUL-1 associates with the 
SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc 
Natl Acad Sci U S A, 1998. 95(19): p. 11324-9. 
67. Nakayama, K.I. and K. Nakayama, Regulation of the cell cycle by SCF-type 
ubiquitin ligases. Semin Cell Dev Biol, 2005. 16(3): p. 323-33. 
68. Bai, C., R. Richman, and S.J. Elledge, Human cyclin F. Embo j, 1994. 13(24): p. 
6087-98. 
69. Fung, T.K., et al., Cyclin F is degraded during G2-M by mechanisms 
fundamentally different from other cyclins. J Biol Chem, 2002. 277(38): p. 35140-
9. 
70. Kong, M., et al., Cyclin F regulates the nuclear localization of cyclin B1 through a 
cyclin-cyclin interaction. Embo j, 2000. 19(6): p. 1378-88. 
71. Li, A. and J.J. Blow, Non-proteolytic inactivation of geminin requires CDK-
dependent ubiquitination. Nat Cell Biol, 2004. 6(3): p. 260-7. 
72. Park, H.J., et al., Anaphase-promoting complex/cyclosome-CDH1-mediated 
proteolysis of the forkhead box M1 transcription factor is critical for regulated 
entry into S phase. Mol Cell Biol, 2008. 28(17): p. 5162-71. 
73. Sivaprasad, U., Y.J. Machida, and A. Dutta, APC/C--the master controller of 
origin licensing? Cell Div, 2007. 2: p. 8. 
74. Clijsters, L., J. Ogink, and R. Wolthuis, The spindle checkpoint, APC/C(Cdc20), 
and APC/C(Cdh1) play distinct roles in connecting mitosis to S phase. J Cell Biol, 
2013. 201(7): p. 1013-26. 
75. Chang, L., et al., Atomic structure of the APC/C and its mechanism of protein 
ubiquitination. Nature, 2015. 522(7557): p. 450-4. 
76. Zhou, Z., et al., Insights into APC/C: from cellular function to diseases and 
therapeutics. Cell Div, 2016. 11: p. 9. 
77. Vodermaier, H.C. and J.M. Peters, APC activators caught by their tails? Cell 
Cycle, 2004. 3(3): p. 265-6. 
78. Fang, G., H. Yu, and M.W. Kirschner, Direct binding of CDC20 protein family 
members activates the anaphase-promoting complex in mitosis and G1. Mol Cell, 
1998. 2(2): p. 163-71. 
79. Vodermaier, H.C. and J.M. Peters, Conspiracy to disarm APC in interphase. Nat 
Cell Biol, 2002. 4(5): p. E119-20. 
80. Moshe, Y., et al., Role of Polo-like kinase in the degradation of early mitotic 
inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl 
Acad Sci U S A, 2004. 101(21): p. 7937-42. 
81. Hansen, D.V., et al., Plk1 regulates activation of the anaphase promoting 
complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction 
of the APC Inhibitor Emi1. Mol Biol Cell, 2004. 15(12): p. 5623-34. 
82. Faesen, A.C., et al., Basis of catalytic assembly of the mitotic checkpoint 
complex. Nature, 2017. 
83. Kim, S. and H. Yu, Mutual regulation between the spindle checkpoint and APC/C. 
Semin Cell Dev Biol, 2011. 22(6): p. 551-8. 
84. Rieder, C.L., et al., The checkpoint delaying anaphase in response to 
chromosome monoorientation is mediated by an inhibitory signal produced by 
unattached kinetochores. J Cell Biol, 1995. 130(4): p. 941-8. 
85. Musacchio, A., The Molecular Biology of Spindle Assembly Checkpoint Signaling 
Dynamics. Curr Biol, 2015. 25(20): p. R1002-18. 
65 
 
86. Kraft, C., et al., Mitotic regulation of the human anaphase-promoting complex by 
phosphorylation. Embo j, 2003. 22(24): p. 6598-609. 
87. Lin, Z., X. Luo, and H. Yu, Structural basis of cohesin cleavage by separase. 
Nature, 2016. 532(7597): p. 131-4. 
88. Zachariae, W., et al., Control of cyclin ubiquitination by CDK-regulated binding of 
Hct1 to the anaphase promoting complex. Science, 1998. 282(5394): p. 1721-4. 
89. Kramer, E.R., et al., Mitotic regulation of the APC activator proteins CDC20 and 
CDH1. Mol Biol Cell, 2000. 11(5): p. 1555-69. 
90. Qiao, X., et al., APC/C-Cdh1: From cell cycle to cellular differentiation and 
genomic integrity. Cell Cycle, 2010. 9(19): p. 3904-12. 
91. Lindon, C. and J. Pines, Ordered proteolysis in anaphase inactivates Plk1 to 
contribute to proper mitotic exit in human cells. J Cell Biol, 2004. 164(2): p. 233-
41. 
92. Zhao, W.M. and G. Fang, Anillin is a substrate of anaphase-promoting 
complex/cyclosome (APC/C) that controls spatial contractility of myosin during 
late cytokinesis. J Biol Chem, 2005. 280(39): p. 33516-24. 
93. Taguchi, S., et al., Degradation of human Aurora-A protein kinase is mediated by 
hCdh1. FEBS Lett, 2002. 519(1-3): p. 59-65. 
94. Nguyen, H.G., et al., Mechanism of Aurora-B degradation and its dependency on 
intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol 
Cell Biol, 2005. 25(12): p. 4977-92. 
95. Stewart, S. and G. Fang, Destruction box-dependent degradation of aurora B is 
mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer 
Res, 2005. 65(19): p. 8730-5. 
96. Singh, S.A., et al., Co-regulation proteomics reveals substrates and mechanisms 
of APC/C-dependent degradation. Embo j, 2014. 33(4): p. 385-99. 
97. Song, L. and M. Rape, Regulated degradation of spindle assembly factors by the 
anaphase-promoting complex. Mol Cell, 2010. 38(3): p. 369-82. 
98. Barford, D., Structural insights into anaphase-promoting complex function and 
mechanism. Philos Trans R Soc Lond B Biol Sci, 2011. 366(1584): p. 3605-24. 
99. Zhang, J., et al., Functional characterization of Anaphase Promoting 
Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim 
Biophys Acta, 2014. 1845(2): p. 277-93. 
100. Zirkle, R.E., Ultraviolet-microbeam irradiation of newt-cell cytoplasm: spindle 
destruction, false anaphase, and delay of true anaphase. Radiat Res, 1970. 
41(3): p. 516-37. 
101. Rieder, C.L. and R.E. Palazzo, Colcemid and the mitotic cycle. J Cell Sci, 1992. 
102 ( Pt 3): p. 387-92. 
102. Cheeseman, I.M., The kinetochore. Cold Spring Harb Perspect Biol, 2014. 6(7): 
p. a015826. 
103. Howell, B.J., et al., Spindle checkpoint protein dynamics at kinetochores in living 
cells. Curr Biol, 2004. 14(11): p. 953-64. 
104. Collin, P., et al., The spindle assembly checkpoint works like a rheostat rather 
than a toggle switch. Nat Cell Biol, 2013. 15(11): p. 1378-85. 
105. van der Horst, A. and S.M. Lens, Cell division: control of the chromosomal 
passenger complex in time and space. Chromosoma, 2014. 123(1-2): p. 25-42. 
106. Czuczman, N.M., et al., Pevonedistat, a NEDD8-activating enzyme inhibitor, is 
active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood, 
2016. 127(9): p. 1128-37. 
66 
 
107. Swords, R.T., et al., Pevonedistat (MLN4924), a First-in-Class NEDD8-activating 
enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic 
syndromes: a phase 1 study. Br J Haematol, 2015. 169(4): p. 534-43. 
108. Taylor, B.F., Arsenite inhibition of mitotic progression. (Ph.D. Dissertation). 2007, 
University of Louisville. 
109. Geley, S., et al., Anaphase-promoting complex/cyclosome-dependent proteolysis 
of human cyclin A starts at the beginning of mitosis and is not subject to the 
spindle assembly checkpoint. J Cell Biol, 2001. 153(1): p. 137-48. 
110. van Zon, W. and R.M. Wolthuis, Cyclin A and Nek2A: APC/C-Cdc20 substrates 
invisible to the mitotic spindle checkpoint. Biochem Soc Trans, 2010. 38(Pt 1): p. 
72-7. 
111. Huang, H.C., et al., Evidence that mitotic exit is a better cancer therapeutic target 
than spindle assembly. Cancer Cell, 2009. 16(4): p. 347-58. 
112. London, N. and S. Biggins, Signalling dynamics in the spindle checkpoint 
response. Nat Rev Mol Cell Biol, 2014. 15(11): p. 736-47. 
113. Yusuf, R.Z., et al., Paclitaxel resistance: molecular mechanisms and 
pharmacologic manipulation. Curr Cancer Drug Targets, 2003. 3(1): p. 1-19. 
114. Li, M., J.P. York, and P. Zhang, Loss of Cdc20 causes a securin-dependent 
metaphase arrest in two-cell mouse embryos. Mol Cell Biol, 2007. 27(9): p. 3481-
8. 
115. Zhou, Y., et al., DNA damage-induced inhibition of securin expression is 




LIST OF ABBREVIATIONS 
ANAPC1 Anaphase Promoting Complex Subunit 1 
ANAPC10 Anaphase Promoting Complex Subunit 10 
ANAPC11 Anaphase Promoting Complex Subunit 11 
ANAPC2 Anaphase Promoting Complex Subunit 2 
ANAPC2-
CTD 
Anaphase Promoting Complex Subunit 2 C-terminal 
Domain 
ANAPC3 Anaphase Promoting Complex Subunit 3 
ANAPC4 Anaphase Promoting Complex Subunit 4 
ANAPC5 Anaphase Promoting Complex Subunit 5 
ANAPC6 Anaphase Promoting Complex Subunit 6 
ANAPC8 Anaphase Promoting Complex Subunit 8 
ANOVA Analysis of Variance 
APC/C Anaphase Promoting Complex/ Cyclosome 
ATP Adenosine Triphosphate 
BCA Bicinchoninic Acid 
Bora Protein Aurora Borealis 
BRCA1 Breast Cancer Type 1 Susceptibility Protein 
BUB3 Budding Uninhibited by Benzimidazoles 3 
68 
 
BUBR1 Budding Uninhibited by Benzimidazoles 1: BUB1B 
CDC20 Cell Division Cycle 20 
CDC25A Cell Division Cycle 25A 
CDH1 CDC20 Homolog 1 
CDK Cyclin-dependent Kinase 
CDK1 Cyclin-dependent Kinase 1 
CDKN Cyclin-dependent Kinase Inhibitor 
CDKN1A Cyclin-dependent Kinase Inhibitor 1A 
CDKN1B Cyclin-dependent Kinase Inhibitor 1B 
CDKN1C Cyclin-dependent Kinase Inhibitor 1C 
CDT1 Chromatin Licensing and DNA Replication Factor 1 
CDT2 Chromatin Licensing and DNA Replication Factor 2 
CENP-A Histone H3-like Centromeric Protein A 
CFE Colony Forming Efficiency 
CHK1 Checkpoint Kinase-1 
CRL Cullin-RING Ligase 
C-terminus Carboxy-terminus 
CUL1 Cullin-1 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
DUB Deubiquitinating Enzyme 
E1 Ubiquitin-activating Enzyme 
E2 Ubiquitin-conjugating Enzyme 
E3 Ubiquitin Ligase 
69 
 
ECL Enhanced Chemiluminescence 
EDTA Ethylenediaminetetraacetic Acid 
EGF Epidermal Growth Factor 
EMI1 Early Mitotic Inhibitor 1 
FBXL F-box/ LRR-repeat Protein 
FBXL1 F-box/ LRR-repeat Protein 1 
FBXO F-box Only Protein 
FBXO1 F-box Only Protein 1 
FBXO5 F-box Only Protein 5 
FBXW F-box/ WD Repeat-containing protein 
FBXW1 F-box/ WD Repeat-containing protein 1 
FBXW7 F-box/ WD Repeat-containing protein 7 
FOXM1 Forkhead Box Protein M1 
G1 Gap 1 
G2 Gap 2 
HECT Homologous to E6-AP C-terminus 
KIFC1 Kinesin Family Member C1 
KMN 
Network KNL1-MIS12-NDC80 Network 
KNL1 Kinetochore Scaffold 1 
LRR Leucine-rich Repeats 
M Mitosis 
MAD1 Mitotic Arrest-deficient 1 
MAD2 Mitotic Arrest-deficient 2 
MCC Mitotic Checkpoint Complex 
70 
 
MDM2 Mouse Double Minute 2 
MELT Met-Glu-Leu-Thr 
MPS1 Monopolar Spindle 1 Kinase 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NEDD8 Neural Precursor Cell Expressed Developmentally Down regulated Protein 8 
NEK2A Never in Mitosis Gene A-related Kinase 2 
N-terminus Amino-terminus 
PBS Phosphate-buffered Saline 
PDB Protein Database 
PHD Plant Homeodomain 
PLK1 Polo-like Kinase 1 
PLK4 Polo-like Kinase 4 
pre-RC Pre-replication Complex 
PTM Post-translational Modifications 
RAD21 Double-strand-break Repair Protein rad21 Homolog 
RBX1 RING-box Protein 1 
RING Really Interesting New Gene 
RNA Ribonucleic Acid 
S Synthesis, DNA Replication 
SAC Spindle Assembly Checkpoint 
SAR Structure Activity Relationship 
SCF SKP/Cullin/F-box-containing Complexes 
siRNA Small Interfering RNA 
71 
 
SKP1 S-phase Kinase-associated Protein 1 
SKP2 S-phase Kinase-associated Protein 2 
TBST Tris-buffered Saline with Tween ® 20 
TP53 Tumor Protein P53 
TPR Tetratricopeptide Repeat 
UBE2C Ubiquitin-conjugating Enzyme E2 C 
UPS Ubiquitin-proteasome System 
USP37 Ubiquitin Carboxyl-terminal Hydrolase 37 
UV Ultraviolet 
WEE1 Wee1-like Protein Kinase 
Zn Zinc 






Home Address: 832 E. Madison St. Apt. A 
Louisville, KY 40204 
 
Telephone:  (859) 274-2876 
 
E-mail Address:  jmhoff08@louisville.edu 
 
EDUCATION: 
2010 – 2014 Sewanee: The University of the South; Sewanee, TN; B.S. in 
Biochemistry 
2014 –Present  University of Louisville; Louisville, KY; Graduate Student in 
Pharmacology and Toxicology 
HONORS & AWARDS: 
2014 – 2016  IPIBS Fellowship, University of Louisville 
2015 Best poster presentation, Masters Student. Ohio Valley 
Society of Toxicology 2015 Annual meeting. Northern 
Kentucky University, Highland Heights, KY 
 
PROFESSIONAL SOCIETY MEMBERSHIPS 




Articles published in refereed journals:
73 
 
1. Preparation of C-arylglycals via Suzuki-Miyaura cross-coupling of 
dihydropyranylphosphates. Leidy, M. R.; Hoffman, J. M.; Pongdee, R. 
Tetrahedron Lett. 54(50): 6889-6891 (2013) 
2. Synthesis of N,N-Diethylbenzamides via a Non-Classical Mitsunobu 
Reaction. Hoffman, J. M.; Miller, J. N.; Gardner, M. E.; LePar, D. R.; 
Pongdee, R. Synth. Commun. 44(7): 976-980 (2014) 
 
Abstracts: 
1. Purification of the C-terminal Domain of ANAPC2 and Evidence 
Supporting the Interaction of Lead Compounds for Inhibition of Mitosis. 
Hoffman, J. M.; Al-Eryani, L.; Saforo, D. J.; Taylor, B. F.; Trent, J. O.; 
Garbett, N. C.; States, J. C., FASEB J. April 2016 30:Ib474 
 
PRESENTATIONS: 
1. Synthesis of N,N-Diethylbenzamides via a Non-Classical Mitsunobu 
Reaction. Hoffman, J. M.; Miller, J. N.; Gardner, M. E.; LePar, D. R.; 
Pongdee, R. 43rd National Organic Chemistry Symposium, June 2013, 
University of Washington, Seattle, WA. (Poster)  
2. Preparation of C-Arylglycals via the Suzuki-Miyaura Cross-Coupling 
Reaction of Cyclic Ketene Acetal Phosphates. Leidy, M. R.; Hoffman, J. 
M.; Pongdee, R. 43rd National Organic Chemistry Symposium, June 2013, 
University of Washington, Seattle, WA. (Poster) 
3. Construction of N,N-Diethylbenzamides Employing a Non-Classical 
Mitsunobu Reaction. Hoffman, J. M.; Miller, J. N.; Gardner, M. E.; LePar, 
D. R.; Pongdee, R. 65th Southeast Regional American Chemical Society 
Meeting, November 2013, Atlanta, GA. (Poster) 
4. New Methods for C-Arylglycal Construction: Suzuki-Miyaura Cross-
Coupling of Dihydropyranylphosphates. Leidy, M. R.; Hoffman, J. M.; 
Pongdee R. 65th Southeast Regional American Chemical Society 
Meeting, November 2013, Atlanta, GA. (Poster) 
5. Inhibiting the Anaphase-Promoting Complex/Cyclosome: An Innovative 
Approach for Cancer Chemotherapy. Udoh, K. T.; Hoffman, J. M.; Trent, 
J. O.; States, J. C., Research!Louisville, November 2015. University of 
Louisville, Louisville, KY. (Poster) 
6. Purification of the C-terminal Domain of ANAPC2 and Evidence 
Supporting the Interaction of Lead Compounds for Inhibition of Mitosis. 
Hoffman, J. M.; Al-Eryani, L.; Saforo, D. J.; Taylor, B. F.; Trent, J. O.; 
Garbett, N. C.; States, J. C., Research!Louisville, November 2015. 
University of Louisville, Louisville, KY. (Poster) 
7. Purification of the C-terminal Domain of ANAPC2 and Evidence 
Supporting the Interaction of Lead Compounds for Inhibition of Mitosis. 
Hoffman, J. M.; Al-Eryani, L.; Saforo, D. J.; Taylor, B. F.; Trent, J. O.; 
Garbett, N. C.; States, J. C., Ohio Valley Society of Toxicology, November 
2015. Northern Kentucky University, Highland Heights, KY. (Poster) 
8. Purification of the C-terminal Domain of ANAPC2 and Evidence 
Supporting the Interaction of Lead Compounds for Inhibition of Mitosis. 
74 
 
Hoffman, J. M.; Al-Eryani, L.; Saforo, D. J.; Taylor, B. F.; Trent, J. O.; 
Garbett, N. C.; States, J. C., Experimental Biology 2016, April 2016. San 
Diego, CA. (Poster) 
9. Purification of the C-terminal Domain of ANAPC2 and Evidence 
Supporting the Interaction of Lead Compounds for Inhibition of Mitosis. 
Hoffman, J. M.; Al-Eryani, L.; Saforo, D. J.; Taylor, B. F.; Trent, J. O.; 
Garbett, N. C.; States, J. C., ASPET 2016 Annual Meeting, April 2016. 
San Diego, CA. (Poster) 
10. Recombinant ANAPC2 Displays Multiple Internal Start Sites and 
Compounds targeting ANAPC2 Decrease Proliferation of Lung Cancer 
Cells in vitro. Hoffman, J. M.; Wainscott N. W.; Taylor B. F.; Trent J. O.; 
States J. C., Research!Louisville 2016, October 2016. Louisville, KY 
(Poster) 
11. Recombinant ANAPC2 Displays Multiple Internal Start Sites and 
Compounds targeting ANAPC2 Decrease Proliferation of Lung Cancer 
Cells in vitro. Hoffman, J. M.; Wainscott N. W.; Taylor B. F.; Trent J. O.; 
States J. C., OVSOT 2016, October 2016. Indianapolis, IN (Poster) 
12. Compounds Targeting the APC/C Induce Mitotic Arrest and Apoptosis in 
Cancer Cells in vitro. Hoffman, J. M., James Graham Brown Cancer 
Center Colloquia on Cancer Biology and Therapeutics, March 2017. 
Louisville, KY (Seminar) 
13. Structure-Activity Relationship Studies of Oxypropanolamines: The 
Importance of Hydrophobicity About the Amine for Maintaining Anti-
Proliferative Effects in Lung Cancer Cells. Hoffman, J. M.; Wainscott, N. 
W.; Taylor, B. F.; Burlison, J. A.; Trent, J. O.; States, J. C., Experimental 
Biology 2017, April 2017. Chicago, IL (Poster) 
 
